Efficacy and Safety of MM-II for Treatment of Knee Pain in Subjects With Symptomatic Knee Osteoarthritis
Public ClinicalTrials.gov record NCT04506463. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Single-administration, Multiple-Dose Study to Demonstrate the Efficacy and Safety of MM-II for Treatment of Knee Pain in Subjects With Symptomatic Knee Osteoarthritis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a phase IIb, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of MM-II in subjects with symptomatic knee OA as compared to matching placebo.
Study identification
- NCT ID
- NCT04506463
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 397 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 40 Years to 99 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 21, 2020
- Primary completion
- May 3, 2022
- Completion
- Aug 9, 2022
- Last update posted
- Aug 28, 2024
2020 – 2022
United States locations
- U.S. sites
- 21
- U.S. states
- 10
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Sunpharma site no. 20 | Birmingham | Alabama | 35209 | — |
| Sunpharma site no. 11 | Tempe | Arizona | 85283 | — |
| Sunpharma site no. 25 | Riverside | California | 92503 | — |
| Sunpharma site no. 26 | San Diego | California | 92103 | — |
| Sunpharma site no. 06 | Stamford | Connecticut | 06905 | — |
| Sunpharma site no. 10 | Lady Lake | Florida | 32159 | — |
| Sunpharma site no. 08 | Lake Worth | Florida | 33461 | — |
| Sunpharma site no. 13 | Maitland | Florida | 32751 | — |
| Sunpharma site no. 22 | Miami | Florida | 33145 | — |
| Sunpharma Site no 27 | Miami | Florida | 33155 | — |
| Sunpharma site no. 12 | Miami | Florida | 33155 | — |
| SunPharma Site no 23 | Miami | Florida | 33176 | — |
| Sunpharma site no. 05 | Sunrise | Florida | 33351 | — |
| Sunpharma site no. 04 | The Villages | Florida | 32159 | — |
| Sunpharma site no. 18 | Flossmoor | Illinois | 60422 | — |
| Sunpharma site no. 07 | Hazelwood | Missouri | 63042 | — |
| Sunpharma site no. 17 | Williamsville | New York | 14221 | — |
| Sunpharma site no. 19 | Edmond | Oklahoma | 73013 | — |
| Sunpharma site no. 09 | Charleston | South Carolina | 29406 | — |
| SunPharma Site No 24 | Columbia | South Carolina | 29206 | — |
| Sunpharma site no. 21 | Fort Mill | South Carolina | 29707 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04506463, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 28, 2024 · Synced Sep 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04506463 live on ClinicalTrials.gov.